ADC Therapeutics SA
$1.05
-$0.04 (-3.67%)
$1.02Day Range$1.09
Key Statistics
Market Cap
$139.16M
Shares Outstanding
127.7M
Primary Exchange
XNYS
Currency
USD
Type
CS
IPO Date
May 15, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$1.09
Day High
$1.09
Day Low
$1.02
Volume
3.32M
VWAP
$1.06
Prev Close
$1.09
Transactions
--
Acc. Volume
--
About ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
PHARMACEUTICAL PREPARATIONSSIC 2834193 employeesBIOPOLE, EPALINGES, V8, 106641 21 653 02 00IPO May 15, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001771910
- Ticker Root
- ADCT
- SIC Code
- 2834
About ADC Therapeutics SA (ADCT) Stock
ADC Therapeutics SA (ADCT) closed the 2026-09-16 session at $1.05, down 3.67% versus the previous close (-0.04). The stock opened at $1.09 and traded between $1.02 and $1.09 during that session. Session trading volume was 3.3M shares. The volume-weighted average price (VWAP) is $1.06.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
ADC Therapeutics SA has a market capitalization of $139.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ADCT is listed on the XNYS exchange. The company employs approximately 193 people. ADC Therapeutics SA is headquartered in EPALINGES, V8. The recorded listing date is 2020-05-15.
On this page you can find market ADCT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.